Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22392284 | 1.00 | CRBN (0.35) | CRBN | |
| SCHEMBL20769505 | 0.74 | CRBN (0.36) | CRBN | |
| SCHEMBL20769510 | 0.74 | CRBN (0.36) | CRBN | |
| SCHEMBL20769512 | 0.74 | CRBN (0.36) | CRBN | |
| SCHEMBL22392234 | 0.68 | CRBN (0.32) | CRBN | |
| SCHEMBL1188908 | 0.67 | CRBN (0.44) | CRBN | |
| SCHEMBL22702293 | 0.67 | CRBN (0.44) | CRBN | |
| SCHEMBL3668437 | 0.67 | CRBN (0.44) | CRBN | |
| SCHEMBL15856673 | 0.64 | ACHE (0.33) | — | |
| SCHEMBL20807103 | 0.63 | CRBN (0.33) | CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | disclosed |
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358972-B2 | Pentacyclic heterocycles | CYP2C19, CYP2C18, XDH | CRBN 2946/4885 |
| US-20200283452-A1 | PENTACYCLIC HETEROCYCLES | CYP2C19, CYP2C18, XDH | CRBN 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.